New Delhi Metallo – beta lactamase – 1 containing Enterobacteriaceae: origin, diagnosis, treatment and public health concern
Jaykaran Charan, Summaiya Mulla, Sridhar Ryavanki, Naresh Kantharia
The Pan African Medical Journal. 2012;11:22. doi:10.11604/pamj.2012.11.22.849

Create an account  |  Sign in
Case studies in Public health Supplement 2 Supplement
"Better health through knowledge sharing and information dissemination "

Review

New Delhi Metallo – beta lactamase – 1 containing Enterobacteriaceae: origin, diagnosis, treatment and public health concern

Cite this: The Pan African Medical Journal. 2012;11:22. doi:10.11604/pamj.2012.11.22.849

Received: 16/05/2011 - Accepted: 11/09/2011 - Published: 13/02/2012

Key words: Antibiotics resistance, Enterobacteriaceae, New Delhi Beta metallo lactamase, carbapenemases

© Jaykaran Charan et al. The Pan African Medical Journal - ISSN 1937-8688. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Available online at: http://www.panafrican-med-journal.com/content/article/11/22/full

Corresponding author: Jaykaran Charan, Department of Pharmacology, Govt. Medical College, Outside Majura Gate, Surat (Gujarat), 395001 India (drjaykaran@yahoo.co.in)


New Delhi Metallo – beta lactamase – 1 containing Enterobacteriaceae: Origin, Diagnosis, Treatment and Public health concern.

 

Jaykaran Charan1,&, Summaiya Mulla2, Sridhar Ryavanki3, Naresh Kantharia1

 

1Department of Pharmacology, Govt. Medical College, Surat, India, 2Department of Microbiology, Govt. Medical College, Surat, India, 3Department of Community Medicine, Govt. Medical College, Surat, India

 

 

&Corresponding author
Jaykaran Charan, Department of Pharmacology, Govt. Medical College, Outside Majura Gate, Surat (Gujarat), 395001 India

 

 

Introduction

Microorganisms existed on this earth millions of years before the evolution of man. Revolution in the medical sciences during the 19th century, along with the advent of antibiotics aroused a hope to do away with the microorganisms of concern to man, but today microbial resistance to antibiotics continues to be a serious threat to mankind. A number of articles published in indexed journals predict that, in near future, we may encounter a group of entirely new bacteria which may not be amenable to any of the presently available antibiotics This could have a tremendous impact on the advanced medical procedures like organ transplantation, bone marrow transplantation and cancer chemotherapy [1]. Kumarasamy et al, in a study published in Lancet Infectious Disease journal, reported that enterobacteriaceae isolated from two centers in India were highly resistant to all antibiotics except colistin and tigecycline.

 

Majority of these organisms carried a novel gene on their plasmid which was named as New Delhi Metallo-betalactamase (NDM -1, bla NDM-1). Kumarasamy et al also reported that isolates from Haryana had a similar genetic finger print. This is indirect evidence for their common origin and, hence a potential epidemic threat [2]. Walsh T et al, in a study published in Lancet Infectious Disease journal, found that seepage and tap water collected from New Delhi contained microorganisms resistant to all known antibiotics except colistin and tigecycline which contain bla NDM -1 gene [3].

 

These studies were received with criticism. There were issues related to the naming of the gene after an Indian city, invalid methodology, and illogical conclusion [4-8]. In the midst of criticism and controversy, one cannot deny the fact regarding existence of a “superbug”, resistant to all known antibiotics and the need to prevent the rapid spread of such organisms. Though the information existed previously, the awareness of NDM - 1 containing microorganisms only came about after the publication of Kumarasamy et al’s study [2]. A PubMed and Google search was done using MeSH term “NDM -1” or “New Delhi Metallolactamase-1”. The authors found 12 articles (Table 1) reporting NDM - 1 gene containing bacteria (reviews, letters, articles related to laboratory investigations were excluded) [9-18].

 

A recently published surveillance study discovered, that enterobacteriaceae containing NDM - 1 were present in New Delhi from as early as 2006 [19]. But, the first significant study addressing the problem of NDM - 1 gene containing multidrug resistant microorganism was a case report by Yong et al [9]. In this case report, carbapenem resistant Klebsiella pneumoniae, isolated from the urine of a 59 year old Swedish resident of Indian origin, was found to be harboring NDM - 1 gene. The patient was suffering from type 2 diabetes with a history of multiple strokes. During his stay in India, he was operated for gluteal abscess at Ludhiana (Punjab), and for decubital ulcer at New Delhi.

 

The problem was again highlighted by Deshpande et al in a study published in Journal of Association of Physicians of India [10]. In this study, out of 24 carbapenem resistant Enterobacteriaceae recovered from a tertiary hospital, 22 were found to be harboring NDM -1 gene. Out of these 22 NDM - 1 positive Enterobacteriaceae, 10 were Klebsiella spp, 9 Escherichia coli, 2 Enterobacter spp and one isolate of Monganella morganii. NDM -1 positive Enterobacteriaceae were also reported from other countries among patients, who had travelled to India, Pakistan and Bangladesh [11-18]. This caused controversy after the publication of Kumarasamy et al [2] and Walsh et al [3], reporting NDM - 1 harboring Enterobacteriaceae in Indian patients and water in New Delhi respectively.

 

What is NDM-1?

NDM - 1(New Delhi Metallo-betalactamase - 1) is a carbapenemase beta lactamase enzyme. This enzyme is coded by blaNDM -1or NDM - 1 gene. This gene encodes, 269 amino acids containing protein, with molecular mass of approx 27.5 kDa [1]. Carbapenemases are beta lactamase which can hydrolyze the beta lactams, particularly carbapenem. They are resistant to clavulanic acid, salbactum and many other commercially available beta lactamase inhibitors.

 

Broadly carbapenemases are categorized into four groups; Class A: Penicillinases, Class B: Metallolactamases, Class C: Cephalosporinase or ampC and Class D: Oxacillinases [20]. NDM -1 belongs to class B- Carbapenemase. The characteristic property of class B carbapenemase is that, they require zinc at their active site; hence they are called as metallolactamases. The activity of these enzymes can be inhibited by Zinc chelating agents like EDTA [21]. Metallolactamases also hydrolyze cephalosporins and penicillins. Aztreonam resist hydrolysis by metallolactamases [21]. The bla NDM -1 gene is accompanied by other genes responsible for resistance to antibiotics, like erythromycin, ciprofloxacillin, rifampicin and chloramphenicol. It is also accompanied by a broad spectrum beta lactamase (CMY -4), also a genetic element, which encodes for efflux pump and its promoters. All these accompanying genes make bla NDM -1 more dangerous in causing multidrug resistance [22].

 

In the Kumarasamy et al study, it was noted that blaNDM -1 also coexisted with amino glycoside resistant genes like blaOXA- 23 and armA [11]. A similar study by Poirel et al, observed that the NDM - 1 gene in a strain of Citrobacter freundii was accompanied by 9 different types of beta lactamase [23]. The blaNDM -1 gene is located on plasmid, which can be easily transferred to other bacteria by conjugation, and it is found to be located on plasmid of different sizes, which predicts its mobility and pathogenesis [24]. NDM -1 positive organism can get colonized in the gut in the absence of any feature of disease. As most of these organisms are normal commensals of the gut, the screening of these organisms is a difficult task [24].

 

 

 

Laboratory detection of NDM -1

Laboratory detection of NDM -1 involves: 1)Identification of the microorganism, 2) Detection of metello -beta- lactamase production and 3)Identification of bla NDM -1 [2,9,10].

 

Identification of bacteria can be done by automated systems like Phoenix or by API 20 E Strips [2]. Elevated Minimum Inhibitory Concentration (MIC) to carbapenem is the foremost event that can indicate the carbapenemase (metallo - beta lactamase and other) production [21]. Elevated MIC predicts carbapenemase production in enterobacteriaceae but it cannot predict total clinical resistance [21]. MIC can be measured by microbroth dilution, agar dilution or by disk diffusion. According to recent guideline by Clinical Laboratory Standards Institute (CLSI), if an organism is resistant to carbapenem in accordance with CLSI cut off points, then there is no further need to go for phenotype testing by other methods like modified hodge. This holds well not only for clinical reporting, but for epidemiological and research purposes. Carbapenem resistant bacteria detection by MIC method, should be further explored for carbapenemase production by phenotypical methods [25]. It is very important to understand that the variability in susceptibility of cabapenem seems to depend on the type of automated system used [26].

 

Production of metallo -beta- lactamase can be identified by disk approximation test (or double disk synergy test) using EDTA as metal chelater. In disk approximation test, clear zone (zone of inhibition) around the beta lactum disk, is increased in the presence of zinc chelator like EDTA. It is observed that imipenem-EDTA combination was most sensitive for metallo beta lactamse production [27]. Metallo beta lactamse can also be confirmed by Etest strip. E test strip of imipenem and imipenem-EDTA combination is used to detect metallo-beta-lactamase production. Three fold or greater decrease in MIC of imipenem in the presence of EDTA indicates the production of metallo-beta-lactamase, but there are possibilities of false positivity and false negativity. False negative results, when MIC of imipenem is less than 4 microgram/ml [27]. False positivity results, in the presence of OXA genes or direct action of EDTA on microorganism by changing former’s permeability [28]. Modified Hodge test can also be used for the same purpose. This is a phenotypic test for confirming the presence of carbapenemase (metallo - beta lactamase) production. Cloverleaf indentation at the intersection of the test organism and standard strain, within the zone of inhibition of carbapenem disk shows positive result for carbapenemase production [29]. The advantage of this method is that even the weak carbapenemase activity enzyme can be detected [21]. Other methods like isoelectric focusing and imipenem hydrolysis can also be used for the same purpose [21]. Presence of bla NDM - 1 can be detected by polymerase chain reaction by the use of specific primer targeting the gene [2,9,10,21].

 

 

Treatment of infection caused by NDM-1 harboring Enterobacteriaceae

Infections caused by such bacteria are associated with high morbidity and mortality. Even though specific data on NDM - 1 positive organisms is not available, there is indirect evidence to suggest that carbapenemase producing Enterobacteriaceae infection is associated with high crude and attributable mortality. In a study by Bores A et al, it was observed that crude mortality and attributable mortality in the patients of carbapenemase producing Kliebsella pneumoniae bacteremia was 71.9% and 50% respectively [30]. In a similar study by Patel G et al, it was noted that mortality among the cases with carbapenemase resistant Klebsiella pneumoniae was significantly more as compared to control (40% Vs 20%). Timely administration of in vitro sensitive antibiotics was not associated with survival [31]. Two classes of antibiotics i.e., polymyxins (colistin) and glycylcyclines (tigecyclines), have shown in vitro activity against NDM - 1 harboring Enterobacteriaceae. On the basis of in vitro sensitivity analysis of 37 British isolates, 50% and 90% MIC for colistin was 0.5 mg/ L and 8 mg/L respectively ,and for tigecycline, it was 1 mg/L and 4 mg/L [32]. In the Kumarasamy study, it was observed that 89% of UK isolates were susceptible to colistin and 64% to tigecycline. Out of all Indian isolates, more than 50% were sensitive to tigecycline and all were sensitive to colistin [2], but the chances of resistance are also high. In the Kumarasamy et al study one isolate (from Chennai) was highly resistant to all known antibiotics. A similar finding was also observed in studies done in Greece and New York [33, 34, 35]. Resistance to colistin and tigecycline should be a reason for worry, as it indicates a return to the pre antibiotic era [32]. Along with resistance, one more limitation of drug therapy in such infections is toxicity. Colistin group was practically abandoned 30 years ago due to its nephrotoxicity. In a study by Souli et al, it was observed that, attributable mortality by colistin containing regimen in patient infected by carbapenemase producing Klebsiella pneumoniae was around 19% [33].

 

Tigecycline is a relatively new antibiotic. In a small number of studies, it was observed that Tigecycline has favorable outcomes in 70% of the patients infected with carbapenem and multidrug resistant organisms. But, a recent US Food and Drug administration update warned about the increase in mortality among patients taking tigecycline as compared to other antibiotics [36]. A combination of tigecycline and colistin has been explored in some studies done for carbapenemase producing Enterobacteriaceae.

 

Cobo J et al , observed that colistin and tigecycline combination is synergistic [37]. Pournaras et al, on the basis of time kill assay, studied the effect of tigecycline alone, and its combination with meropenam and colistin, on carbapenemase producing Klebsiella pneumoniae strain. It was observed that as a single agent, none of the three antibiotics (tigecycline, meropenam and colistin) showed bactericidal concentration. Tigecycline and colistin, when given together produced bactericidal effect [38]. Some studies also reported the successful treatment of pan resistant Enterobacteriaceae with combination therapy of colistin and tigecycline [39]. Combinations using aztreonam or any other monobactum which are resistant to hydrolysis by metallolactamases are recommended by some studies. Here it is important to understand that NDM - 1 containing bacterial strain may also have other carbapenemase like ampC or ESBLs which may hydrolyze the aztreonam. So inhibitors of these enzyme (like NXL104) should be the part of such combination therapy [40]. Fosfomycine is also suggested for use in carbapenemase producing pan resistant Enterobacteriaceae [41].

 

 

Public health concerns and way forward

India has quite a lot of skilled physicians and nurse practitioners. Over the last two decades, the economic boom in India has led to the expansion of infrastructure with medical facilities, at par with the medical care that the west has to offer. While some small countries may be viable as alternatives for minor surgical procedures, India is the only mainstream option that offers a comprehensive solution for any and all medical needs, and it does this with the highest levels of service, facilities, and professional skills. A complex transplant or bypass procedure can be achieved with a fraction of the cost as compared to U.S.A [42].

 

Several published articles particularly case reports show link, between NDM - 1 containing pan resistant Enterobacteriaceae and India. It has been argued, that these “superbugs” originated in Indian subcontinent [2,3,9]. Various factors like over the counter use of antibiotics, irrational use of antibiotics, easy accessibility of higher antibiotics, poor sanitation, high prevalence of diarrhea and overcrowding are considered responsible for development and spread of these organisms [9]. A Lancet Infectious Disease study, warned patients against going to India for medical treatment as they may get infected with these organisms, which ultimately cost more than “the short term saving” [2]. This conclusion was questioned by press, politicians, scientists as well as the first author of the same study [4]. Recent study which shows the presence of NDM - 1 harboring organism in New Delhi water, but absence of such organism in Cardiff water, indicates that the problem is more severe in countries like India. Instead of denial, there is a need to understand the severity of the situation, the burden it can pose in future, and to develop the necessary strategies to halt the development and spread of NDM -1. Steps are already being taken in western countries [24,43,44] and similar or more aggressive steps are needed in India.

 

An active surveillance system encompassing various microorganisms should be put in place. There is a need for an appropriate system by which recent trend of bacterial susceptibility to various antibiotics can be notified at various levels. There is also a need of National Reference Laboratory and Research Institute for systematic study and vigilance of antibiotic resistance. Monitoring of prescription is required to be done regularly in hospitals and irrational or inappropriate use of antibiotics be discouraged. Unethical promotional policies of pharmaceutical companies should be taken seriously as it is duly observed, that many of the claims made in promotional material distributed by pharmaceutical companies, are not supported by valid evidence [45]. Clinicians instead of relying on pharmaceutical companies for information related to any drug including antibiotics, try to find out for themselves through journals or by participating in CMEs, conferences. Knowledge and effective management of locally endemic infectious diseases needs to be given more emphasis in both undergraduate and postgraduate curriculum [1]. Clear cut antibiotic policies in every hospital should be implemented and the use of reserved antibiotics left for cases of utmost need only.

 

The same has been advocated by the WHO in its 2011 World Health Day theme “Combat Antimicrobial Resistance: No Action Today, No Cure Tomorrow”. Stringent laws to curb selling of over the counter (OTC) antibiotics have to be discussed and implemented at the national level. Facilities for detection of NDM - 1 are to be made accessible to all hospitals and some molecular or diagnostic probes should be developed for rapid detection of this gene in bacteria [46]. This is an opportune time for health policy specialists, scientists, academicians and government official to collectively analyse the present situation and take some concrete steps for prevention as well as spread of this resistance.

 

 

Conclusion

Because of the irrational use of antibiotics more and more microorganisms are developing resistance to available antibiotics. Enterobactareaceae class of microorganisms is clinically very important and emergence of resistance to almost all antibiotics in this class should be matter of concern to clinicians and health authorities. Clinicians should be trained about the rational use of antibiotics and legislative changes should be done to prevent widespread and irrational use of antibiotics.

 

 

Acknowledgments

I would like to acknowledge Dr. Preeti Yadav, Associate Professor, Department of Pharmacology, Govt. Medical College, Surat, for suggestion and help in preparing of this manuscript.

 

 

Competing interests

The authors declare no competing interest.

 

 

Authors’ contributions

Ideation: JK, SM, Literature search: JK, SM, SR, NDK, Analysis of Literature: JK, SM, SR, NDK, Manuscript writing: JK, SM, Proof reading: SR, NDK. All the authors have read and approved the final version of the manuscript.

 

 

Tables

Table 1: Studies reporting NDM-1 containing enterobacteriaceae

 

 

References

  1. Abdul Ghafur K. An obituary - On the death of antibiotics. Journal of the association of physicians of India. 2010;58:143-44. This article on PubMed

  2. Kumarasamy KK, Toleman MA, Walsh TR, et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect Dis. 2010 Sep;10(9):597-602. This article on PubMed

  3. Walsh TR, Weeks J, Livermore DM, Toleman MA. Dissemination of NDM -1 positive bacteria in the New Delhi environment and its implications for human health: an environmental point prevalence study. Lancet Infect Dis. 2011;11:355-62. This article on PubMed

  4. Kant S, Haldar P. Is NDM - 1 actually being imported to UK from India. Indian J Public Health. 2010;54:151-54. This article on PubMed

  5. Mahajan A, Tandon VR. New Delhi metallo (Beta - Lactamase 1): Fact or Fiction. JK Science. 2010;12:109

  6. Nataraj G. New Delhi metallo beta - lactamase: What is in a name?J Postgrad Med. 2010 Oct-Dec;56(4):251-2. This article on PubMed

  7. Singh A R. Science, Names Giving and Names Calling: Change NDM -1 to PCM. Mens Sana Monogr. 2011 Jan;9(1):294-319. This article on PubMed

  8. Kaul TK. Medical Tourism and New Delhi Metallo b lactamase 1 A Concern and Threat. J Anaesthesiol Clin Pharmacol. 2010 Oct;26(4):437-8. This article on PubMed

  9. Yong D, Toleman MA, Giske CG, Cho HS, Sundman K, Lee K, et al. Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. Antimicrob Agents Chemother. 2009 Dec;53(12):5046-54. This article on PubMed

  10. Deshpande P, Rodrigues C, Shetty A, Kapadia F, Hedge A, Soman R. New Delhi metallo-beta lactamase (NDM-1) in Enterobacteriaceae: treatment options with carbapenems compromised.J Assoc Physicians India. 2010 Mar;58:147-9. This article on PubMed

  11. Karthikeyan K, Thirunarayan MA, Krishnan P. Coexistence of blaOXA -23 with blaNDM - 1 and armA in clinical isolates of Acinetobacter baumanii from India. J Antimicrob Chemother. 2010;65:2253-2270. This article on PubMed

  12. Poirel L, Lagrutta E, Taylor P, Pham J, Nordmann P. Emergence of Metallo-b-lactamase-NDM-1-Producing multidrug resistant Escherichia coli in Australia. Antimicrobial Agents and Chemotherapy. 2010;54:4914-4916. This article on PubMed

  13. Wu HS, Chen TL, Chen ICJ, Huang MS, Wang FD, Fung CP, et al. First Identification of a patient colonized with Klebsiella pneumonia carrying blaNDM-1 in Taiwan. J Chin Med Assoc. 2010;73:596-598. This article on PubMed

  14. Struelens MI, Monnet DL, Magiokaros AP, Santos O Conner F, Giesecke J, the Europian NDM- 1 survey participants. New Delhi matallo - beta - lactamase 1 - producing enterobacteriaceae: emergence and response in Europe. Euro Surveill. 2010 Nov 18;15(46). pii: 19716. This article on PubMed

  15. Chihara S, Okuzumi K, Yamamoto Y, Oikawa S, Hishinuma A. First case of New Delhi metallo - b- lactamase 1 producing Escherichia coli infection in Japan. Clin Infect Dis. 2011;52:152-155. This article on PubMed

  16. Mulvey MR, Grant JM, Plewes K, Roscoe D, Boyd DA. New Delhi metallo - beta- lactamase in Klebsiella pneumonia and Escherichia coli, Canada. Emerg Infect Dis. 2011;17:103-106. This article on PubMed

  17. Zarfel G, Martin H, Leither E, Salzer HJF, Feierl G, Masoud L, et al. Emergence of New Delhi metallo - beta- lactamase, Australia. Emerg Infect Dis. 2011;17:129-130. This article on PubMed

  18. Sidjabat H, Nimmo GR, Walsh TR, Binotto E, Htin A, Hayashi Y, et al. Carbapenam resistance in Klebsiella pneumonia due to New Delhi metallo - beta - lactamase.Clin Infect Dis. 2011 Feb 15;52(4):481-4. This article on PubMed

  19. Castanheira M, Deshpande LM, Mathai D, Bell JM, Jones RN, Mendes RE. Early dissemination of NDM-1- and OXA-181-producing Enterobacteriaceae in Indian hospitals: report from the SENTRY Antimicrobial Surveillance Program (2006-2007). Antimicrob Agents Chemother. 2011 Mar;55(3):1274-8. This article on PubMed

  20. Poirel L, Pitout JD, Nordmann P. Carbapenamases: molecular diversity and clinical consequences. Future Microbiol. 2007;2:501-12. This article on PubMed

  21. Queenan AM, Bush K. Carbapenemases: the versatile beta - lactamases. Clin Microbiol Rev. 2007;20:440-458. This article on PubMed

  22. Moellering RC. NDM-1: A cause for worldwide concern. New Eng J Med. 2010;363:2377-2379. This article on PubMed

  23. Poirel L, Ros A, Carricajo A et al. Extremely drug-resistant Citrobacter freundii isolate producing NDM-1 and other carbapenemases identified in a patient returning from India. Antimicrob Agents Chemother. 2011 Jan;55(1):447-8. This article on PubMed

  24. Bonomo RA. New Delhi metallo - beta -lactamase and multidrug resistance: A global SOS?. Clin Infect Dis. 2011;52:485-487. This article on PubMed

  25. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: twentieth information supplement update M100 -S20-U: The Institute; 2010.

  26. Tenove FC, Kalsi RK, Williams RB, Carry S, Stocker D, Lonswey JK, et al. Carbapenem resistance in Klebsiella pneumonia not detected by automated susceptibility testing. Emerg Infect Dis. 2006;12:1209-1213. This article on PubMed

  27. Yan JJ, Hsueh PR, Tsai SH, Chuang CL. Comparison of the double disk, combined disk and Etest methods for detecting metallo - beta- lactamases in gram negative bacilli. Diagn Microbiol Infect Dis. 2004;49:5-11. This article on PubMed

  28. Chu YW, Cheung TKM, Ngan JYW, Kam KM. EDTA susceptibility leading to false detection of metallo - beta- lactamase in Pseudomonas aeruginosa by Etest and in imipenem - EDTA disk method. Int J Antimicrob Agents. 2005;26:340-41. This article on PubMed

  29. Lee KY, Chong HB, Shin YA, Kim D, Yong, Yum JH. Modified Hodge and EDTA disk synergy tests to screen metallo - beta -lactamase producing strain of pseudomonas an Acinetobacter species. Clin Microbiol Infect. 2001 Feb;7(2):88-91. This article on PubMed

  30. Borer A, Saidel-Odes L, Riesenberg K, et al. Attributable mortality rate for carbapenem - resistannt Klebsiella pneumonia bacteremia. Infect Control Hosp Epidemiol. 2009;30:972-6. This article on PubMed

  31. Patel G, Huprikar S, Factor SH, Jenkins SG, Calfee DP. Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect Control Hosp Epidemiol. 2008;29:1099-106. This article on PubMed

  32. Pillai DR. New Delhi metallo -beta -lactamase - 1 in Enterobacteriaceae: emerging resistance. CMAJ. 2011;183:59-64. This article on PubMed

  33. Souli M, Kontopidou FV, Koratzanis E et al. In vitro activity of tigecycline against multiple-drug-resistant, including pan-resistant, Gram-negative and Gram-positive clinical isolates from Greek hospitals.Antimicrob Agents Chemother. 2006 Sep;50(9):3166-9. This article on PubMed

  34. Antoniadou A, Kontopidou F, Poulakou G et al. Colistin-resistant isolates of Klebsiella pneumoniae emerging in intensive care unit patients: first report of a multiclonal cluster. J Antimicrob Chemother. 2007 Apr;59(4):786-90. This article on PubMed

  35. Landman D, Georgescu C, Martin DA, Quale J. Polymyxins revisited. Clin Microbiol Rev. 2008;21:449-65. This article on PubMed

  36. US Food and Drug Administration. FDA drug safety podcast for healthcare professionals: increased risk of death with Tygacil (tigecycline) compared to other antibiotics used to treat similar infections. Silver Spring (MD) US Department of Health and Human Services; 2010. Available at www.fda.gov/Drugs/DrugSafety/DrugSafetyPodcast/ucm224896.htm. Accessed 16 May 2011.

  37. Cobo J, Morosini MI, Pintado V, Tato M, Samaranch N, Baquero F, et al. Use of tigecycline for the treatment of prolonged bacteremia due to a multiresistant VIM -1 and SHV - 12 beta-lactamase- producing Klebsiella pneumoniae epidemic clone. Diagn Microbiol Infect Dis. 2008;60:319-322. This article on PubMed

  38. Pournaras S, Vrioni G, Neou E, Dendrinos J, Dimitroulia E, Poulou A, et al. Activity of tigecycline alone and in combination with colistin and meropenem against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae strains by time-kill assay. Int J Antimicrob Agents. 2011 Mar;37(3):244-7. This article on PubMed

  39. Humphries RM, Kelesidis T, Bard JD, Ward KW, Bhattacharya D, Lewinsky MA. Successful treatment of pan-resistant Klebsiella pneumoniae pneumonia and bacteraemia with a combination of high dose tigecycline and colistin. J Med Microbiol. 2010;59: 1383-1386. This article on PubMed

  40. Livermore DM, Mushtaq S, Warner M, Zhang J, Maharjan S, Doumith M, et al. Activity of NXL104 combinations with ceftazidime an aztreonam against carbapenemase - producing Enterobacteriaceae. Antimicrob Agents Chemother. 2010;55:390-4. This article on PubMed

  41. Falagas ME, Kastoris AC, Kapaskelis AM, Karageorgopoulos DE. Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum beta-lactamase producing, Enterobacteriaceae infections: a systematic review. Lancet Infect Dis. 2010 Jan;10(1):43-50. This article on PubMed

  42. Lakhani N. NHS “could save millions” by flying patients to India. The Independent. Available at: http://www.independent.co.uk/life-style/health-and-families/health-news/nhs-could-save-millions-by-flying-patient-to-india-1870215.html. Accessed 16 May 2011.

  43. HPA. Health protection report. London: Health protection agency, 2009. Available at: http://www.hpa.uk/hpr/archives/2009/news0409.htm. Accessed 11 May 2011

  44. Centers for disease control and prevention. Detection of Enterobacteriaceae isolates carrying metallo-beta-lactamase - United States, 2010. MMWR Morb Mortal Wkly Rep. 2010;59:750. This article on PubMed

  45. Charan J, Yadav P, Saxena D, Kantharia ND. Drug advertisements published in Indian Medical Journals: Are they ethical?. J Pharm Bioallied Sci. 2011 Jul;3(3):403-6. This article on PubMed

  46. Raghunath D. New metallo beta lactamase NDM-1. Indian J Med Res. 2010;132:478-481. This article on PubMed

 

 

 

 

 

 


The Pan African Medical Journal articles are archived on Pubmed Central. Access PAMJ archives on PMC here

Volume 28 (September - December 2017)

Article tools

Rate this article

Altmetric

PAMJ is a member of the Committee on Publication Ethics
Next abstract

PAMJ is published in collaboration with the African Field Epidemiology Network (AFENET)
Currently tracked by: DOAJ, AIM, Google Scholar, AJOL, EBSCO, Scopus, Embase, IC, HINARI, Global Health, PubMed Central, PubMed/Medline, Ulrichsweb, More to come . Member of COPE.

ISSN: 1937-8688. © 2017 - Pan African Medical Journal. All rights reserved